1/17
01:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was downgraded by analysts at
Wall S
Low
Report
Estrella Immunopharma (NASDAQ:ESLA) was downgraded by analysts at
Wall S
1/6
02:02 pm
esla
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Medium
Report
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
1/5
08:30 am
esla
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
12/4
08:00 am
esla
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Medium
Report
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
11/22
02:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
High
Report
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
11/22
02:11 am
esla
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
High
Report
Estrella Immunopharma (NASDAQ:ESLA) was upgraded by analysts at
Wall Str
11/3
11:24 am
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
High
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
11/3
08:00 am
esla
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Medium
Report
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
10/31
01:02 pm
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.